Table 1.
Comparison of clinicopathological characteristics between Han and Zhuang women with hormone receptor-positive breast cancer.
| Variable | Total(n = 337) | Han(n = 236) | Zhuang(n = 101) | χ2 | P-value |
|---|---|---|---|---|---|
| Age (years) | 0.179 | ||||
| Median (range) | 41 (26–50) | 44 (31–52) | |||
| Tumor invasion depth | 0.020 | 0.990 | |||
| ≤2 cm | 72 | 50 | 22 | ||
| >2 cm, ≤5 cm | 241 | 169 | 72 | ||
| >5 cm | 24 | 17 | 7 | ||
| No. of lymph nodes | 1.309 | 0.520 | |||
| 0 | 16 | 10 | 6 | ||
| 1–3 | 185 | 134 | 51 | ||
| ≥4 | 136 | 92 | 44 | ||
| ER status | 0.958 | 0.328 | |||
| Negative | 29 | 18 | 11 | ||
| Positive | 308 | 218 | 90 | ||
| PR status | 0.125 | 0.724 | |||
| Negative | 26 | 19 | 7 | ||
| Positive | 311 | 217 | 94 | ||
| HER-2 status | 0.763 | 0.383 | |||
| Negative | 267 | 184 | 83 | ||
| Positive | 70 | 52 | 18 | ||
| Pathological type | 4.578 | 0.101 | |||
| Invasive ductal carcinoma | 185 | 138 | 47 | ||
| Invasive lobular carcinoma | 90 | 60 | 30 | ||
| Other | 62 | 38 | 24 |
HER-2 positive indicates positive for HER-2 by fluorescence in situ hybridization or chromogenic in situ hybridization test or (+++) in immunohistochemistry test according to National Comprehensive Cancer Network guidelines 2011. Positivity for ER and PR defined according to American Society of Clinical Oncology and College of American Pathologists 2010 guidelines, which recommended positivity criteria for ER and PR as ≥1% of positive nuclear staining.
HER-2, human epidermal growth factor receptor 2; PR, progesterone receptor; ER, estrogen receptor.